You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the YUPELRI (revefenacin) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR YUPELRI


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for yupelri

Trial ID Title Status Sponsor Phase Start Date Summary
NCT05165485 ↗ Phase 4 COPD and Suboptimal Inspiratory Flow Rate Not yet recruiting Mylan Inc. Phase 4 2021-12-01 Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
NCT05165485 ↗ Phase 4 COPD and Suboptimal Inspiratory Flow Rate Not yet recruiting Theravance Biopharma Phase 4 2021-12-01 Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
NCT05207111 ↗ Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution Completed Mylan Pharmaceuticals Phase 1 2021-09-23 Single-Dose Fasting Bioavailability Study of Revefenacin Inhalation Solution, 175 mcg/3 mL in 24 Healthy Chinese Adult Male and Female Volunteers. This study will evaluate the safety and tolerability of Revefenacin Inhalation Solution in the Chinese population. For the determination of the pharmacokinetic disposition of the formulations, The bioavailability of Revefenacin Inhalation Solution, 175 mcg/3 mL will be assessed through various pharmacokinetic parameters derived from the plasma concentration-time curves of revefenacin and its active metabolite, THRX-195518.
NCT05207111 ↗ Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution Completed Mylan Inc. Phase 1 2021-09-23 Single-Dose Fasting Bioavailability Study of Revefenacin Inhalation Solution, 175 mcg/3 mL in 24 Healthy Chinese Adult Male and Female Volunteers. This study will evaluate the safety and tolerability of Revefenacin Inhalation Solution in the Chinese population. For the determination of the pharmacokinetic disposition of the formulations, The bioavailability of Revefenacin Inhalation Solution, 175 mcg/3 mL will be assessed through various pharmacokinetic parameters derived from the plasma concentration-time curves of revefenacin and its active metabolite, THRX-195518.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for yupelri

Condition Name

Condition Name for yupelri
Intervention Trials
Chronic Obstructive Pulmonary Disease 1
Healthy Volunteers Bioavailability Study 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for yupelri
Intervention Trials
Respiratory Aspiration 2
Pulmonary Disease, Chronic Obstructive 1
Lung Diseases, Obstructive 1
Lung Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for yupelri

Trials by Country

Trials by Country for yupelri
Location Trials
United States 13
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for yupelri
Location Trials
Texas 1
Tennessee 1
South Carolina 1
Oregon 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for yupelri

Clinical Trial Phase

Clinical Trial Phase for yupelri
Clinical Trial Phase Trials
Phase 4 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for yupelri
Clinical Trial Phase Trials
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for yupelri

Sponsor Name

Sponsor Name for yupelri
Sponsor Trials
Mylan Inc. 2
Theravance Biopharma 1
Mylan Pharmaceuticals 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for yupelri
Sponsor Trials
Industry 3
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.